関連する実験動画

Updated: Sep 9, 2025

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

Psoriatic Arthritis の患者における生物学的治療の二次的な失敗の発生率と予測要因

Fadi Kharouf¹, Ali AlHadri², Shangyi Gao³

¹F. Kharouf, Gladman Krembil Psoriatic Arthritis Program, Centre For Prognosis Studies in the Rheumatic Diseases, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, Ontario, Canada; Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

The Journal of rheumatology

|September 1, 2025

まとめ

病原性関節炎 (PsA) では,生物学的病原性関節炎薬 (bDMARDs) の二次的な失敗が一般的です. 発症時のより高い発症率と特定の治療の選択は,時間の経過とともに治療の効果が低下するリスクに影響する.

科学分野:

リウマトロジ
免疫学
薬理学について

背景:

病原性関節炎 (PsA) の管理において,病原性関節炎薬 (bDMARDs) の二次的な失敗は重要な課題となっている.
二次性不全の頻度,発生率,リスク要因を理解することは,PSAにおける患者のアウトカムを最適化するために極めて重要です.

研究の目的:

PsA患者のコホートでbDMARDの二次失敗の頻度と発生率を決定する.
PsAにおける二次性不全の発生に関連する臨床的および治療的要因を特定する.

主な方法:

bDMARDsを開始したPsA患者の前向きな観察コホート研究が行われました.
応答は1年後に定義され,二次的な失敗は応答の喪失または臨床判断に基づいて評価された.
コックス回帰モデルを用いて,二次性障害の危険因子を分析した.

主要な成果:

PsA患者の半数以上 (54. 8%) が1年後にbDMARDに反応したが,反応者の35. 6%が二次的な失敗を経験した.
基礎値より高いSJCとPASIスコアは,二次性不全のリスクの増加と関連していました.
他のbDMARDと比較してTNF阻害剤 (TNFi) の使用,第一線bDMARDの開始,およびより最近の治療開始日付は,二次失敗の減少と関連していました.

結論:

bDMARDに対する二次的な失敗は,牛皮質関節炎で頻繁に見られる.
患者の病気の特徴と特定の治療戦略の両方が,PsAにおける二次失敗の可能性に影響を与えるようです.

さらに関連する動画

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

関連する概念動画

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Psychological and Sociocultural Causes of Schizophrenia

Psychological and Sociocultural Causes of Schizophrenia

Schizophrenia, a complex psychiatric disorder, has been historically misunderstood. Early psychological theories attributed its origins to childhood trauma and unresponsive parenting. However, contemporary research largely rejects these notions, favoring the vulnerability-stress hypothesis. This model proposes that individuals with a genetic predisposition to schizophrenia may develop the disorder following exposure to significant environmental stressors. Notably, studies on high-risk...

Factors Affecting Protein-Drug Binding: Patient-Related Factors

Factors Affecting Protein-Drug Binding: Patient-Related Factors

Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

The JAK-STAT Signaling Pathway

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...